Analysts at Leerink Partnrs raised their FY2026 EPS estimates for shares of Travere Therapeutics in a research note issued to investors on Tuesday, February 11th. Leerink Partnrs analyst J. Schwartz ...

Research analysts at Leerink Partnrs upped their Q3 2025 EPS estimates for shares of Waters in a note issued to investors on ...

Fintel reports that on February 13, 2025, Leerink Partners upgraded their outlook for Genmab A (NasdaqGS:GMAB) from Market ...

Fintel reports that on February 13, 2025, Leerink Partners downgraded their outlook for 10x Genomics (NasdaqGS:TXG) from ...

Leerink Partners analyst Daina Graybosch maintained a Buy rating on Century Therapeutics (IPSC – Research Report) yesterday and set a price ...

Leerink Partners analyst Daina Graybosch maintained a Buy rating on Nkarta (NKTX – Research Report) yesterday and set a price target of $7.00.

Genmab (GMAB) and Sonic Automotive (SAH) are climbing 5% and 3%, respectively, after investment banks issued favorable notes ...

Thryv Therapeutics Inc., a clinical-stage biotechnology company pioneering novel therapies for cardiovascular diseases, is ...

NeuroPace (Nasdaq:NPCE) today announced that it intends to sell common stock in an underwritten public offering worth $65 ...

A live webcast, if recorded, of each presentation can be accessed under “Events & Presentations” in the Investors section of the Company’s website at www.fatetherapeutics.com. The archived webcast ...

Humana forecast annual profit slightly below Wall Street estimates on Tuesday, signaling that costs from its ...

The failure in adjuvant melanoma could cause BMS and Opdualag to miss out on a market opportunity that is nearly twice as large as its current approved indication, according to analysts.